Westfield Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,748
| Closed | -$467K | – | 228 |
|
|
2022
Q3 | $467K | Sell |
1,748
-1,169
| -40% | -$248K | ﹤0.01% | 222 |
|
|
2022
Q2 | $595K | Sell |
2,917
-10
| -0.3% | -$2.04K | ﹤0.01% | 221 |
|
|
2022
Q1 | $616K | Sell |
2,927
-1,112
| -28% | -$242K | ﹤0.01% | 224 |
|
|
2021
Q4 | $969K | Sell |
4,039
-292,883
| -99% | -$75.3M | 0.01% | 218 |
|
|
2021
Q3 | $84M | Buy |
296,922
+105,080
| +55% | +$34.4M | 0.51% | 71 |
|
|
2021
Q2 | $66.4M | Buy |
191,842
+189,985
| +10,231% | +$57.6M | 0.4% | 92 |
|
|
2021
Q1 | $519K | Buy |
1,857
+44
| +2% | +$11.9K | ﹤0.01% | 236 |
|
|
2020
Q4 | $444K | Sell |
1,813
-19
| -1% | -$4.9K | ﹤0.01% | 244 |
|
|
2020
Q3 | $520K | Hold |
1,832
| – | – | ﹤0.01% | 224 |
|
|
2020
Q2 | $490K | Buy |
+1,832
| New | +$551K | ﹤0.01% | 222 |
|
|
2019
Q4 | – | Sell |
-2,414
| Closed | -$562K | – | 237 |
|
|
2019
Q3 | $562K | Sell |
2,414
-40
| -2% | -$9.31K | ﹤0.01% | 223 |
|
|
2019
Q2 | $574K | Sell |
2,454
-234,796
| -99% | -$54.2M | ﹤0.01% | 228 |
|
|
2019
Q1 | $56.1M | Sell |
237,250
-3,809
| -2% | -$1.2M | 0.43% | 78 |
|
|
2018
Q4 | $72.5M | Buy |
241,059
+23,758
| +11% | +$7.58M | 0.62% | 62 |
|
|
2018
Q3 | $76.8M | Sell |
217,301
-54,883
| -20% | -$18.9M | 0.54% | 61 |
|
|
2018
Q2 | $79M | Sell |
272,184
-27,695
| -9% | -$7.79M | 0.59% | 52 |
|
|
2018
Q1 | $82.1M | Sell |
299,879
-11,970
| -4% | -$3.72M | 0.63% | 51 |
|
|
2017
Q4 | $99.3M | Buy |
311,849
+54,157
| +21% | +$17.4M | 0.76% | 35 |
|
|
2017
Q3 | $80.7M | Sell |
257,692
-62,987
| -20% | -$18.7M | 0.62% | 54 |
|
|
2017
Q2 | $87M | Sell |
320,679
-38,428
| -11% | -$10.2M | 0.74% | 39 |
|
|
2017
Q1 | $98.2M | Buy |
+359,107
| New | +$102M | 0.84% | 32 |
|
|
2016
Q4 | – | Sell |
-301,521
| Closed | -$94.4M | – | 262 |
|
|
2016
Q3 | $94.4M | Buy |
301,521
+55,858
| +23% | +$16.5M | 0.76% | 41 |
|
|
2016
Q2 | $59.4M | Sell |
245,663
-126,805
| -34% | -$33.4M | 0.49% | 68 |
|
|
2016
Q1 | $97M | Sell |
372,468
-141,199
| -27% | -$37.3M | 0.74% | 45 |
|
|
2015
Q4 | $157M | Buy |
513,667
+512,977
| +74,344% | +$147M | 1.06% | 23 |
|
|
2015
Q3 | $201K | Sell |
690
-34
| -5% | -$11.2K | ﹤0.01% | 260 |
|
|
2015
Q2 | $292K | Sell |
724
-319,277
| -100% | -$128M | ﹤0.01% | 274 |
|
|
2015
Q1 | $135M | Buy |
320,001
+319,311
| +46,277% | +$126M | 0.78% | 37 |
|
|
2014
Q4 | $234K | Hold |
690
| – | – | ﹤0.01% | 308 |
|
|
2014
Q3 | $228K | Hold |
690
| – | – | ﹤0.01% | 296 |
|
|
2014
Q2 | $218K | Hold |
690
| – | – | ﹤0.01% | 309 |
|
|
2014
Q1 | $211K | Buy |
+690
| New | +$219K | ﹤0.01% | 324 |
|
Other funds holding BIIB
Westfield Capital Management's BIIB Position: Q4 2022 in Review
Westfield Capital Management sold out of Biogen (BIIB) in Q4 2022, closing a stake of 1,748 shares — an estimated $467K sold.
Westfield Capital Management first reported a position in BIIB in Q1 2014 and held it in 32 quarters. The position peaked at $157M in Q4 2015. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.
- Westfield Capital Management reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
- Westfield Capital Management sold 1,748 Biogen shares in Q4 2022, an estimated $467K.
- Westfield Capital Management first reported a position in Biogen in Q1 2014 and held it in 32 quarters.
- Westfield Capital Management's Biogen position peaked at $157M in Q4 2015.
- 1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.
Based on Westfield Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.